PC
CTMX icon

PointState Capital’s CytomX Therapeutics CTMX Stock Holding History

PointState Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-154,000
Closed -$4.38M – 172
2018
Q1 		$4.38M Buy
+154,000
New +$4.4M 0.05% 117

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

PointState Capital's CTMX Position: Q2 2018 in Review

PointState Capital sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 154,000 shares — an estimated $4.38M sold.

PointState Capital first reported a position in CTMX in Q1 2018 and held it in 1 quarter. The position peaked at $4.38M in Q1 2018. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

  • PointState Capital reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
  • PointState Capital sold 154,000 CytomX Therapeutics shares in Q2 2018, an estimated $4.38M.
  • PointState Capital first reported a position in CytomX Therapeutics in Q1 2018 and held it in 1 quarter.
  • PointState Capital's CytomX Therapeutics position peaked at $4.38M in Q1 2018.
  • 142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.